Clinical Care Options Hepatitis - HCV http://clinicaloptions.com/hepatitis.aspx New treatment data and educational activities for hepatitis treating clinicians en-us Clinical Care Options Hepatitis - HCV http://images.imedoptions.com/img.asp?img=cco/CCO_Hep_RSS.gif http://clinicaloptions.com/hep Expert Analysis: Update on Investigational Agents in HCV: 2007 http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Investigational%20HCV.aspx Nezam H. Afdhal, MD, FRCPI, Ira M. Jacobson, MD, and David R. Nelson, MD review data from the meeting in Boston. Exper Recap: Update on Investigational Agents in HCV: 2007 http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Virtual%20Presentation%20Programs/Investigational%20HCV%20ER.aspx Watch and listen as Ira M. Jacobson, MD, reviews key data on investigational HCV agents presented at the 2007 Boston liver disease meeting. Development of Model for End-Stage Liver Disease Improved Graft and Overall Survival Rates After Liver Transplantation in HCC Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Special%20Issues/Capsules/598.aspx 3-year graft and survival rates following liver transplant in HCC patients with and without HCV infection improved after development of MELD Case: Management of a 38-Year-Old Male on Methadone Maintenance Therapy Who Presents With PCP http://clinicaloptions.com/HIV/Treatment%20Updates/Simple/Interactive%20Case%20Challenges/Case%202.aspx William G. Powderly, MD, discusses selection of initial therapy for a 38-year-old recovering IDU male with HIV/HCV coinfection who presents with PCP. Significant Proportion of HCV/HIV-Coinfected Patients Refuse HCV Therapy in Large German Cohort http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Special%20Issues/Capsules/276.aspx HCV/HIV-coinfected patients often decline anti-HCV therapy despite tolerability and efficacy of peginterferon alfa-2a plus ribavirin Robust Response to Peginterferon alfa-2b Plus Ribavirin Among HCV-Infected IV Drug Users on Opioid Maintenance in Large German Cohort http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Special%20Issues/Capsules/253.aspx HCV-infected IV drug users undergoing opioid maintenance therapy achieve response rates similar to patients not undergoing opioid therapy when adjusted for age, HCV genotype, and baseline HCV RNA level. 28 Days of Telaprevir, Peginterferon alfa-2a, and Ribavirin Followed by 44 Weeks of Peginterferon alfa-2a and Ribavirin Demonstrates Potent and Prolonged Antiviral Efficacy in Small Group of HCV Genotype 1 Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/175.aspx Telaprevir shown to be safe and effective during combination treatment with peginterferon alfa-2a plus ribavirin among a small cohort of mostly minority patients. Biweekly Administration of Controlled-Release Recombinant Interferon alfa-2b Appears to Be Effective and Well Tolerated in Patients With HCV Genotype 1 http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/LB10.aspx Phase IIa study of controlled-release recombinant interferon alfa-2b demonstrates potent antiviral activity and is well tolerated among HCV genotype 1-infected, treatment-naive patients Favorable HCV, HBV Outcomes in HCV/HBV-Coinfected Patients Treated With Peginterferon alfa-2a Plus Ribavirin http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Special%20Issues/Capsules/233.aspx Peginterferon alfa-2a plus ribavirin therapy resulted in similar rates of HCV clearance when compared with HCV-monoinfected patients and led to HBsAg clearance in a significant proportion of patients at end-of-treatment follow-up GI-5005, a Yeast-Based Immunotherapy, Results in Dose-Dependent HCV-Specific Cellular Immune Responses and ALT Normalization in Chronic Hepatitis C Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/1304.aspx Novel immunotherapy, GI-5005, results strong immune response, and some antiviral activity in chronic hepatitis C patients. HCV Polymerase Inhibitor R1626 Has High Genetic Barrier to Resistance With Potent Antiviral Effects in Chronic Hepatitis C http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/1298.aspx R1626 with or without peginterferon alfa-2a and ribavirin potently suppresses viral replication in patients chronically infected with HCV genotype 1 Peginterferon/Ribavirin/Nitazoxanide Increases Sustained Virologic Response Rate in Interferon-Naive HCV Genotype 4 Patients vs Peginterferon/Ribavirin http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/178.aspx Study suggests potential SVR benefit to interferon-experienced patients with addition of nitazoxanide to standard-of-care peginterferon alfa-2a and ribavirin in genotype 4 HCV patients R7128, Promising Therapy for HCV Genotype 1 Nonresponders, Demonstrates Potent Antiviral Activity and Is Well Tolerated Over 14 days http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/LB9.aspx R7128 shown to be well tolerated with significant viral suppression and no viral rebound in HCV genotype 1-infected nonresponders over 14 days. PROVE2 Study Shows High SVR Rates With Combination Treatment With Telaprevir, Peginterferon alfa-2a, and Ribavirin in Treatment-Naive Patients Infected With HCV Genotype 1 http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/80.aspx Telaprevir in combination with peginterferon alfa-2a plus ribavirin demonstrates strong virologic suppression with minimal adverse events. PROVE 1 Study: Combination Telaprevir, Peginterferon alfa-2a, and Ribavirin Therapy Has Rapid and Sustained Antiviral Activity in HCV Genotype 1 Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/177.aspx Telaprevir in combination with peginterferon alfa-2a and ribavirin results in high SVR rates treatment-naive HCV genotype 1 patients but is associated with increased incidence of dermatologic and gastrointestinal adverse events. Multiple Infusions of Bavituximab Safe and Active Against HCV http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/53.aspx Bavituximab administered twice weekly for 2 weeks in HCV patients appears safe and well tolerated at doses up to 6 mg/kg Telaprevir Resistance Mutations Emerge Among Hepatitis C Patients Who Relapse Following Sequential Therapy of Telaprevir, Peginterferon alfa-2a, and Ribavirin http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/50.aspx Telaprevir resistance mutations detected following 2 weeks of telaprevir-based therapy and standard peginterferon alfa-2a/ribavirin therapy HCV Polymerase Inhibitor R1626 Combined With PegIFN/RBV Results in greater than 80% of HCV Genotype 1 Patients Achieving RVR http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/167.aspx High dosages of R1626 produce robust antiviral effects but are associated with high rates of cytopenias and gastrointestinal adverse events in HCV genotype 1 patients. Albinterferon alfa-2b Achieves SVR in Some Hepatitis C Patients Who Failed Previous Interferon-Based/Ribavirin Therapy http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/51.aspx Significant antiviral activity of higher doses of albinterferon alfa-2b in previous interferon/ribavirin HCV nonresponders may not translate into higher SVR rates. Advances in HCV Management Strategies With Approved Agents http://cms.clinicaloptions.com/hepatitis/conference%20coverage/boston%202007/tracks/approved%20hcv/approved%20hcv.aspx Raymond T. Chung, MD, Mitchell L. Shiffman, MD, and Mark S. Sulkowski, MD review new data from the meeting in Boston. Short Duration VCH-759 Demonstrates Potent Antiviral Activity in HCV Genotype 1a and 1b Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/LB11.aspx Novel HCV NS5B polymerase inhibitor, VCH-759, shown to be safe and effective in genotype 1a and 1b patients during short-term study. HCV FibroSURE and FIBROSpect II Comparable for Fibrosis Staging in Chronic Hepatitis C Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Approved%20HCV/Capsules/1368.aspx Serodiagnostic marker panel tests FibroSURE and FIBROSpect II have similar positive and negative predictive abilities for staging METAVIR F2-F4 fibrosis. Albinterferon Alfa-2b Plus Ribavirin for Chronic Hepatitis C Genotype 1 Achieves Comparable Efficacy to Peginterferon alfa-2a Plus Ribavirin With Fewer Injections http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Investigational%20HCV/Capsules/180.aspx Albinterferon alfa-2b every 2 weeks plus ribavirin treatment of HCV genotype 1 patients results in fewer workdays missed than peginterferon alfa-2a every week plus ribavirin.